Loading
A small randomised study of how to help people at higher risk of pancreatic cancer decide about genetic testing and a multi-cancer blood test.
REGENERATE (NCT07787156) is a randomised interventional study sponsored by Brigham and Women's Hospital with Pancreatic Cancer Action Network, Exact Science Corporation, Dana-Farber Cancer Institute and others. Its primary outcomes are the feasibility of completing genetic and multi-cancer testing, acceptability and fidelity; Exact Sciences and the Pancreatic Cancer Action Network are collaborators.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 80 participants, a start on 15 October 2026 and primary completion expected in September 2028.
Shares Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Exact Sciences (Abbott), Pancreatic ductal adenocarcinoma.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/